🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccination schedules, an unexpected name appears unexpectedly: Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by casting doubt on coronavirus shots during the pandemic and has focused upon alleged fatalities after Covid immunization in her recent time at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Schedule

Agency leaders planned to unveil major revisions to the childhood vaccination calendar recently, bringing the US with the Danish vaccine program, according to reports – a substantial departure that would place the US out of step with many the world with no evidence for benefit. This reveal has been pushed back until the next year.

Instead of the director of the vaccine center, Høeg is set to address the audience at the meeting. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

A New Direction at the Agency

Høeg's temporary position could signify a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad solidify control at the regulatory agency – and it signals a renewed priority upon dismantling already-approved immunizations at the FDA.

The new acting director has frequently advocated for discontinuing some pediatric shot schedules in the US to become more similar to Denmark's approach, a society with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

To date public appearances, she has kept her attention on vaccines – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Doubts Over Background

Dr. Høeg has no obvious experience in medication creation, oversight or management, which has been typical for past heads of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a large organization. She is not an expert in drug approvals.”

Previous directors of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that prior appointees who ran the center have had.”

CDER has an vast range of responsibilities at the agency, Woodcock emphasized.

“Everybody just focuses on the new drug program, but the generic drug division approves thousands of off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and so forth, and all of those must be looked after,” Woodcock noted. “The responsibility you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a major administrative aspect to the position, which manages more than 5,000 staff members. “It is a massive administrative position, if you perform it correctly,” she added.

Response and Disputed Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this selection signifies greater collaboration among regulatory chiefs on immunizations, a spokesperson stated that the “inquiries are based on incorrect assumptions”.

“Her resume is consistent with the responsibilities of her role,” the official explained, citing the period Høeg spent counseling the FDA commissioner on “medication safety and oversight research, including computerized risk analysis and vaccine surveillance”.

As acting director, Dr. Høeg inherits the commissioner’s new fast-track approval initiative, a controversial one-day medication authorization process that reportedly worried her predecessors. “How are these drugs being picked for this voucher program? Who takes the choices?” Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

Overall, he stated, “the Food and Drug Administration seems to be moving towards less stringent oversight of all drugs, with the exception of immunizations.”

Public History on Immunizations

With vaccines, Høeg has a more established, if troubling, track record, some experts have noted. She authored a analysis using non-validated public submissions to estimate the rate of myocarditis after COVID-19 immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Part of her “desired changes” for the new government included altering regulations for new vaccines and ending “unnecessary” vaccines, she stated following the vote on a online show. At the agency, Dr. Høeg has according to sources suggested preventing young men from receiving Covid vaccines.

“She’s an all-around true believer who begins with her beliefs and works backwards to fit the data in a very misleading, fraudulent manner,” Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with other dissenters, {like|